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A highly sensitive fluorescent light-up probe for
real-time detection of the endogenous protein
target and its antagonism in live cells†
Junlong Geng,‡a Walter L. Goh,‡b Chongjing Zhang,c David P. Lane,b Bin Liu,*ac
Farid Ghadessy*b and Yen Nee Tan*a
Real-time detection and monitoring of cancer-related biomolecular
interactions in live cells are of paramount importance for disease
diagnostics and drug screening. Herein, we developed a target-specific
fluorescent light-up probe for cellular detection of Mdm2, the key
negative regulator of the p53 tumour suppressor protein. Conjugation
of a uniquely designed fluorogen (TPECM) with aggregation induced-
emission properties, to a specific p53-derived peptide (12.1Pep) targeting
Mdm2, yielded a cell-permeable probe (TPECM–12.1Pep) with turn-on
fluorescence properties for real-time live cell imaging of Mdm2. This
specific light-up probe is almost non-fluorescent in its isolated state but
is highly emissive uponbinding toMdm2, enabling quantitative detection
of bothMdm2 and its antagonism. Using amodel compound (Nutlin-3a),
we demonstrate that the as-developed probes can be used to screen
p53–Mdm2 inhibiting drug candidates, both in vitro and in cells.
Furthermore, the probe activity can be accurately monitored in cells
using a fluorescently activated cell sorting machine. These features will
expedite research in the areas of drug discovery, clinical diagnostics and
fundamental cell biology.
Introduction, experimental
The Mdm2 protein is the key negative regulator of p53, dubbed
‘‘the guardian of the Genome’’ and master regulator of cellular
fate.1 Mdm2 binding leads to ubiquitination of p53, and this
modification targets p53 for rapid proteasome-dependent
degradation in cells.2 The finely tuned relationship between
p53 and Mdm2 levels is often corrupted in cancer cells, either
through disabling point mutations in p53 or overproduction of
Mdm2 due to gene amplification.3 Both events abrogate the
pivotal cellular responses to stress (cell cycle arrest, apoptosis)
mediated by p53, thus engendering permissive conditions for
tumour growth and differentiation.4 Mdm2 has therefore
become a therapeutic target of interest, with numerous small
molecules and peptidic antagonists in clinical development.5
Reagent tools facilitating real-time Mdm2 detection, particularly
in live cells, will therefore have significant use in diagnostic,
drug-screening and basic biological research applications.
Currently, the most widely utilized approaches for Mdm2
detection are fluorescence in situ hybridization, fluorescence
correlation spectroscopy, immunohistochemistry, and immuno-
blotting.6 These strategies typically involve complex molecular
labelling and/or tedious sample preparation, which are not
readily amenable to real-time monitoring in live cells. Recently
described approaches have utilized fluorescent fusion proteins
to study p53–Mdm2 interactions in live cells.7 In addition to the
convoluted technical procedures, the large size of the GFP tag
may affect the function or interactions of the target proteins,
leading to specious observations. In this regard, small molecule
modified fluorescent probes show promising advantages in
studying biomolecular interactions in view of their size and easy
modification.8 More recently, a molecular rotor was conjugated to a
specific Mdm2-interacting peptide, enabling fluorescence turn-on
upon Mdm2 binding in vitro.9 However, such probes show high
fluorescence background with limited response (B2-fold) to Mdm2
protein, and are not readily suited for real-time cellular studies.
Thus it is highly desirable to develop a new class of fluorescent
probes with an improved signal-to-noise ratio and cell-penetrance
that could facilitate real-time Mdm2 detection and imaging in the
native cellular environment.
In this study, a target-specific fluorescent light-up probe with
the unique characteristic of aggregation-induced emission (AIE) has
been developed for detection of Mdm2 and drug screening
applications (Scheme 1). AIE fluorogens (e.g. tetraphenylethene
(TPE)) usually show weak fluorescence in the isolated states, but
exhibit strong fluorescence in the aggregated state as a result of
the restriction of intramolecular rotation and prohibition of
energy dissipation via non-radiative channels.10 Typically, AIE
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fluorogens with longer emission wavelength are well suited for
biodetection and bioimaging due to the low auto-fluorescence
background and phototoxicity.11 Therefore, for cellular imaging,
TPECM dye (Scheme 1) with an excitation wavelength compatible
to a 405 nm laser was designed as it displays an orange-red emission
color upon aggregation.12 The peptide, MPRFMDYWEGLS (12.1Pep),
a p53-derived sequence engineered for high affinity binding to
Mdm2 protein through phage display,9,13 was chosen as a response
ligand for Mdm2 detection. The conjugation of 12.1Pep with the
TPECM fluorogen yielded the target-specific light-up probe, TPECM–
12.1Pep, which enables live-cell detection of Mdm2 and screening of
Mdm2 antagonisms.
Results and discussion
TPECM was synthesized through conjugation of the dicyanovinyl
group with TPE molecules.12 The incorporation of dicyanovinyl
groups elongated the conjugation system of TPE, thus yielding
fluorogens with both red-shifted absorption and emission as
compared with those of TPE. In addition, attachment of a methyl
group onto the dicyanovinyl group helps improve the stability of
TPECM in the presence of biothiol agents present in the culture
medium.12 TPECM shows an absorption peak at 385 nm and
almost no emission in THF (Fig. S1, ESI†). The fluorescence
intensity evolution of TPECM was studied by monitoring the
emission intensity from equal molar concentrations of TPECM
in THF/water mixtures with various water fractions ( fw). TPECM
exhibits low fluorescence emission at lower fw values (0–70%) but
increases exponentially when fw increased from 80% to 99%
(Fig. 1). The corresponding fluorescence intensity of TPECM at
99% fw isB90-fold higher than that in pure THF, demonstrating
the unique AIE feature of the TPECM fluorogen.
The TPECM–12.1Pep probe was subsequently prepared through
a copper(I) catalyzed click-reaction between azide-functionalized
TPECM and alkyne-functionalized 12.1Pep (Scheme S1, ESI†),
followed by HPLC purification. The integrity and purity of the
probe were characterized using MALDI-TOF MS spectra (Fig. S2,
ESI†). UV-vis absorption and fluorescence spectra of the TPECM
dye and TPECM–12.1Pep in water mixture are shown in Fig. 1B.
Although they exhibited similar absorption profiles in the 350 to
500 nm range, their emission spectra were very different. A strong
orange-red emission was observed for TPECM with a maxima at
603 nm while TPECM–12.1Pep is almost non-fluorescent under the
same conditions (inset in Fig. 1B). The high fluorescence of TPECM
is due to the aggregation of hydrophobic TPECM molecules in
aqueousmedia, determined by laser light scattering (LLS) measure-
ment with an average size of 80 nm (Fig. S3, ESI†). The conjugation
of TPECM with 12.1Pep yields TPECM–12.1Pep with improved
water solubility over the hydrophobic TPECM fluorogen as con-
firmed by the undetectable LLS signal. In addition, the probe
remains nearly non-fluorescent in DMEMmedium and PBS buffer,
facilitating its potential application as an effective and specific
light-up probe with a low background signal for biological detec-
tion and imaging in a cellular context.
To investigate the fluorescence response from binding of the
TPECM–12.1Pep probe to Mdm2 protein, increasing concentra-
tions of purified recombinant Mdm2 were titrated against a fixed
100 nM TPECM–12.1Pep. Fluorescence intensities of TPECM–
12.1Pep/Mdm2 mixtures increased gradually with increasing
Mdm2 concentrations (Fig. 1C). An enhancement factor of 13
is observed for the TPECM–12.1Pep in the presence of 2500 nM
Mdm2. This significant fluorescence enhancement is due to the
restriction of freely rotating TPECMmolecules when the 12.1Pep
docks into Mdm2’s hydrophobic binding pocket (Scheme 1).14
The calculated apparent Kd (149.6  52.07 nM) for TPECM–
12.1Pep–Mdm2 binding is consistent with the previous reports
of 12.1Pep–Mdm2 interaction.9,13 This turn-on signal is pro-
foundly weaker in the presence of non-specific proteins (IgG
and BSA) at the same mass concentrations (Fig. 1D), suggesting
high binding specificity.
The demonstration of Mdm2 specific activity in vitro inspired us
to next explore the utilization of TPECM–12.1Pep in live cells. The
H1299 Ecdysone-Inducible (H1299-EI) system allows controllable
Scheme 1 Schematic illustration of Mdm2 detection and drug screening.
Fig. 1 (A) Variations in I/I0 of TPECM with the change in the water fraction
in the THF/water mixture. (B) UV-vis (dashed-dotted line) and PL (solid line)
spectra of TPECM and TPECM–12.1Pep at 2 mM in water. The inset shows
the image of the TPECM and TPECM–12.1Pep (right) solutions under
UV-lamp excitation at 365 nm. (C) Fluorescence intensity evolution of
100 nM TPECM–12.1Pep at different concentrations of Mdm2 protein
(N-terminal domain) and (D) its comparison with other control proteins.
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and constitutive expression of p53 in H1299 cells using the
inducer ponasterone A (Pon-A).15 As cellular Mdm2 levels are
directly up-regulated by p53, induction of H1299-EI cells carrying
wild-type p53 (H1299-EI-p53WT) leads to an increase in endogenous
Mdm2. We first evaluated cytotoxicity of TPECM–12.1Pep on live
cells using theMTT assay. No significant cytotoxicity was observed in
H1299-E1 cells after 24 h and 48 h incubation with TPECM–12.1Pep
at different concentrations (2 to 20 mM). Cell viabilities remain
490% (Fig. S4, ESI†), suggesting little to no probe-induced
cytotoxicity, making TPECM–12.1Pep highly suitable for cellular
imaging. Next, T22 reporter cells, carrying a p53 driven
b-galactosidase reporter gene, were used to assess the cell
permeability and activity of TPECM–12.1Pep.16 The extent of
TPECM–12.1Pep cellular uptake can be assessedwhen benchmarked
against Nutlin-3a, a prototypical antagonist which abrogates p53–
Mdm2 interaction by binding the Mdm2 N-terminal hydrophobic
pocket. A concentration-dependent increase in b-galactosidase
activity is observed upon TPECM–12.1Pep treatment, similar to
the Nutlin-3a induced response (Fig. S5, ESI†). This strongly
suggests cellular uptake and binding of TPECM–12.1Pep to
endogenous Mdm2, resulting in the observed increase in p53
activity.
To visualize cellular Mdm2 levels, TPECM–12.1Pep was added
to either induced, or uninduced, wild type p53 expressing H1299-EI
cells, and imaged using confocal laser scanning microscopy
(CLSM). Mdm2-dependent fluorescence is strikingly higher in
induced H1299-EI-p53WT (Fig. 2A) compared to p53-null control
cells not induced for p53 expression (Fig. 2B). Auto-fluorescence
was also not observed in H1299-EI-p53WT cells without TPECM–
12.1Pep treatment (Fig. S6, ESI†), suggesting a turn-on fluorescence
resulting from the specific interaction of endogenous Mdm2 with
TPECM–12.1Pep. The anti-Mdm2 antibody (2A9) was next used to
visualize Mdm2 localization in H1299-EI-p53WT live-cells that were
p53-induced and TPECM–12.1Pep treated. Fluorescence images of
the probe and 2A9 antibody labeled with FITC show a high degree
of co-localization, further implying specific interaction in cells
(Fig. S7, ESI†). To obtain a quantitative analysis of this interaction,
flow cytometry was used to evaluate the intracellular fluores-
cence of H1299-EI-p53WT with and without Pon-A induction.
The mean fluorescence intensity of H1299-EI-p53WT was B3-fold
over uninduced cells (Fig. 2C), demonstrating the quantifiable
measure of Mdm2 protein levels within the complex cellular
environment in live cells. As Mdm2 is a direct transcriptional target
of p53, TPECM–12.1Pep would be valuable as a live-cell imaging
tool for drug discovery and understanding p53 biology in cells.5,17
A key requirement for such a utility would be an Mdm2-induced
fluorescence that is critically sensitive to p53’s transcriptional state.
The fluorescence response of TPECM–12.1Pep was further evalu-
ated using a panel of cells with different p53 and Mdm2 status.
Unlike p53-wild type expressing cells, p53–Mdm2 double-knockout
cells (DKO), and H1299-EI cells expressing either of the two
transcriptionally inactive p53 point mutants (H1299-EI-p53G245S
and H1299-EI-p53R248Q) showed significantly lower levels of
fluorescence activity when treated with TPECM–12.1Pep
(Fig. 2D–F). Notably, western blot analysis using the total cell
lysates of the same cells showed a strong correlation between
cellular Mdm2 protein levels and the fluorescence intensity
within each cell line (Fig. 2G), further exemplifying target
specificity and conditional sensitivity of TPECM–12.1Pep as a
facile bioimaging probe for real-time detection of Mdm2 in
live cells.
Given the major role Mdm2 plays in regulating p53 levels,
significant efforts have gone into developing antagonists of this
key interaction, with several small molecules and peptides
currently in pre-clinical development.4,17,18 TPECM–12.1Pep
acts as a conditionally fluorescent p53 proxy, and is potentially
useful to screen competitive antagonists that can displace it
from the Mdm2 binding pocket. To explore the utility of the
TPECM–12.1Pep probe in small molecule drug screening, we
investigated the sensitivity of the probe to Nutlin-3a, a current
preclinical compound for p53–Mdm2 inhibition.18 Fluores-
cence intensity was measured after either Nutlin-3a, or its less
active enantiomer, Nutlin-3b was added to pre-formed TPECM–
12.1Pep–Mdm2 complexes. A marked decrease in fluorescence
intensity was observed with the addition of Nutlin-3a in a
concentration dependent manner. In contrast, the weakly binding
Nutlin-3b enantiomer showed significantly reduced activity
(Fig. 3A). Nutlin-induced displacement could also be seen in a
similar fashion when whole-cell lysate from p53-induced H1299-
EI-p53WT cells was used in place of purified Mdm2 protein
(Fig. 3B), demonstrating potential drug screening or diagnostic
applications for TPECM–12.1Pep in complex biological samples.
To evaluate this application in live cells, H1299-EI-p53WT
cells expressing p53/Mdm2 were pre-treated with Nutlin-3a
followed by TPECM–12.1Pep incubation and imaged as before.
Fig. 2 CLSM live-cell images of (A) H1299-EI-WTp53, (B) H1299-EI-
p53/, (D) H1299-EI-p53G245S, (E) H1299-EI-p53R248Q and (F) p53/
Mdm2/DKO cells after incubation with 2 mM TPECM–12.1Pep. Images
have the same scale bar of 40 mm. (C) Flow cytometry histograms of live
H1299-EI-WTp53 cells without any treatment (black) and treated with the
TPECM–12.1Pep probe after incubation with (red) and without (blue) Pon-A
induction, respectively. (G) Whole-cell lysate western blot of DKO and
H1299-EI cells showing respective protein levels of p53 and Mdm2 before
and after PonA-A induction.
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Nutlin-3a pre-treatment was able to block and ablate TPECM–
12.1Pep turn-on fluorescence from cellular Mdm2 binding (Fig. 3C
and D), demonstrating the potential for a direct observable approach
for drug screening using fluorescence microscopy in live-cells.
Conclusions
In conclusion, we report a facile, cell-permeable, conditionally
fluorescent probe that is able to sensitively detect changes in
endogenous Mdm2 protein levels in live cells. More specifically,
the TPECM–12.1Pep probe described in this work facilitates
Mdm2 detection in vitro and also enables real-time live cell
imaging, which can be used as a target-specific molecular
sensing tool for drug screening and cancer diagnostics. To
the best of our knowledge, this is the first demonstration of
fluorescence light-up response for Mdm2 detection in live cells.
In addition, this specially designed imaging probe can not only
detect the levels of Mdm2 in live cells, but also the activity of
p53 which drives Mdm2 expression. The specific interaction
between TPECM–12.1Pep and Mdm2 protein was also demon-
strated through the use of a known Mdm2 small molecule
antagonist, and hence holds great potential for drug-screening
platforms using complex cell lysates or live cells. The capability
of TPECM–12.1Pep to sense cellular events through the detec-
tion of an endogenous protein target could be harnessed for
upstream biological applications. Further development of such
target-specific light-up probes with near-infrared emission
wavelength and improved target selectivity will undoubtedly
be useful in forwarding basic research as well as exploring
cancer diagnostics and clinical applications in in vivo systems.
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